1. Monash Health
  2. Monash Health research
  3. Articles
Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/28291
Full metadata record
DC FieldValueLanguage
dc.contributor.authorQuach H.en
dc.contributor.authorSpencer A.en
dc.contributor.authorKalff A.en
dc.date.accessioned2021-05-14T09:31:36Zen
dc.date.available2021-05-14T09:31:36Zen
dc.date.copyright2012en
dc.date.created20121127en
dc.date.issued2012-11-27en
dc.identifier.citationAmerican Journal of Hematology. 87 (12) (pp 1089-1095), 2012. Date of Publication: December 2012.en
dc.identifier.issn0361-8609en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/28291en
dc.description.abstractThe clinical development of lenalidomide (RevlimidTM), then pomalidomide (ActimidTM) as members of immunomodulatory drugs (IMiDs) for the treatment of multiple myeloma (MM), exemplifies how insight into disease biology can lead to design of effective therapeutic agents. Increased experience and understanding of IMiD's diverse biological effects has lead to rational design of lenalidomide-based treatment-regimens over recent years. However, much about lenalidomide is yet to be understood and fully exploited. Here, we review what is known of lenalidomide's biological effects, clinical certainties and uncertainties in the treatment of MM, and explore its future potential with other synergistic therapeutic agents. © 2012 Wiley Periodicals, Inc.en
dc.languageEnglishen
dc.languageenen
dc.publisherWiley-Liss Inc. (111 River Street, Hoboken NJ 07030-5774, United States)en
dc.titleLenalidomide in multiple myeloma: Current status and future potential.en
dc.typeReviewen
dc.type.studyortrialReview article (e.g. literature review, narrative review)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1002/ajh.23234en
dc.publisher.placeUnited Statesen
dc.identifier.pubmedid22641420 [http://www.ncbi.nlm.nih.gov/pubmed/?term=22641420]en
dc.identifier.source52035313en
dc.identifier.institution(Quach, Kalff, Spencer) Myeloma Research Group, Australian Centre for Blood Diseases, Monash University, Clayton, VIC, Australia (Quach) Department of Clinical Haematology, Monash Medical Centre, Clayton, VIC, Australia (Quach, Spencer) Department of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia (Kalff, Spencer) Department of Clinical Haematology, Alfred Hospital, Melbourne, VIC, Australiaen
dc.description.addressH. Quach, Myeloma Research Group, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Faculty of Medicine, Nursing and Health Sciences, Level 4, 246 Clayton Rd, Clayton, VIC 3168, Australia. E-mail: hang.quach@monash.eduen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2013 Elsevier B.V., All rights reserved.en
dc.identifier.authoremailQuach H.; hang.quach@monash.eduen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeReview-
Appears in Collections:Articles
Show simple item record

Page view(s)

16
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.